Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

fluticasone furoate/vilanterol (Breo Ellipta)

Notes:

- Quantity Limits: No
- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

<u>Initiation (new start) criteria</u>: Non-formulary fluticasone furoate/vilanterol (Breo Ellipta) will be covered on the prescription drug benefit when the following criteria are met:

 Patient has documented contraindication, intolerance*, or treatment failure to a trial of fluticasone propionate/salmeterol inhalation powder (Wixela Inhub, Advair Diskus, or generics), fluticasone propionate/salmeterol inhalation aerosol (Advair HFA), and budesonide/formoterol (Symbicort)

Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously: Non-formulary fluticasone furoate/vilanterol (Breo Ellipta) will be covered on the prescription drug benefit when the following criteria are met:

 Patient has documented contraindication, intolerance*, or treatment failure to a trial of fluticasone propionate/salmeterol inhalation powder (Wixela Inhub, Advair Diskus, or generics), fluticasone propionate/salmeterol inhalation aerosol (Advair HFA), and budesonide/formoterol (Symbicort)

<u>Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously</u>: Non-formulary fluticasone furoate/vilanterol (Breo Ellipta) will be covered on the prescription drug benefit when the following criteria are met:

 Patient has documented contraindication, intolerance*, or treatment failure to a trial of fluticasone propionate/salmeterol inhalation powder (Wixela Inhub, Advair Diskus, or generics), fluticasone propionate/salmeterol inhalation aerosol (Advair HFA), and budesonide/formoterol (Symbicort)

kp.org

Revised: 08/11/22 Effective: 10/06/22



